Glucuronidation of Psilocin and 4-Hydroxyindole by the Human UDP-Glucuronosyltransferases

被引:51
作者
Manevski, Nenad [2 ]
Kurkela, Mika [1 ]
Hoglund, Camilla [1 ]
Mauriala, Timo [1 ]
Court, Michael H. [3 ]
Yli-Kauhaluoma, Jari [2 ]
Finel, Moshe [1 ]
机构
[1] Univ Helsinki, Fac Pharm, Ctr Drug Res, FI-00014 Helsinki, Finland
[2] Univ Helsinki, Fac Pharm, Div Pharmaceut Chem, FI-00014 Helsinki, Finland
[3] Tufts Univ, Sch Med, Dept Pharmacol & Expt Therapeut, Boston, MA 02111 USA
基金
芬兰科学院; 美国国家卫生研究院;
关键词
HUMAN LIVER-MICROSOMES; HUMAN URINE; UGT; HALLUCINOGENS; EXPRESSION; SUBSTRATE; 1A6; METABOLISM; STABILITY; KINETICS;
D O I
10.1124/dmd.109.031138
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We have examined the glucuronidation of psilocin, a hallucinogenic indole alkaloid, by the 19 recombinant human UDP-glucuronosyltransferases (UGTs) of subfamilies 1A, 2A, and 2B. The glucuronidation of 4-hydroxyindole, a related indole that lacks the N,N-dimethylaminoethyl side chain, was studied as well. UGT1A10 exhibited the highest psilocin glucuronidation activity, whereas the activities of UGTs 1A9, 1A8, 1A7, and 1A6 were significantly lower. On the other hand, UGT1A6 was by far the most active enzyme mediating 4-hydroxyindole glucuronidation, whereas the activities of UGTs 1A7-1A10 toward 4-hydroxyindole resembled their respective psilocin glucuronidation rates. Psilocin glucuronidation by UGT1A10 followed Michaelis-Menten kinetics in which psilocin is a low-affinity high-turnover substrate (K-m = 3.8 mM; V-max = 2.5 nmol/min/mg). The kinetics of psilocin glucuronidation by UGT1A9 was more complex and may be best described by biphasic kinetics with both intermediate (K-m1 = 1.0 mM) and very low affinity components. The glucuronidation of 4-hydroxyindole by UGT1A6 exhibited higher affinity (K-m = 178 mu M) and strong substrate inhibition. Experiments with human liver and intestinal microsomes (HLM and HIM, respectively) revealed similar psilocin glucuronidation activity in both samples, but a much higher 4-hydroxyindole glucuronidation rate was found in HLM versus HIM. The expression levels of UGTs 1A6-1A10 in different tissues were studied by quantitative real-time-PCR, and the results, together with the activity assays findings, suggest that whereas psilocin may be subjected to extensive glucuronidation by UGT1A10 in the small intestine, UGT1A9 is likely the main contributor to its glucuronidation once it has been absorbed into the circulation.
引用
收藏
页码:386 / 395
页数:10
相关论文
共 35 条
  • [21] Evaluation of atypical cytochrome P450 kinetics with two-substrate models: Evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites
    Korzekwa, KR
    Krishnamachary, N
    Shou, M
    Ogai, A
    Parise, RA
    Rettie, AE
    Gonzalez, FJ
    Tracy, TS
    [J]. BIOCHEMISTRY, 1998, 37 (12) : 4137 - 4147
  • [22] Evaluation of 5-hydroxytryptophol and other endogenous serotonin (5-hydroxytryptamine) analogs as substrates for UDP-glucuronosyltransferase 1A6
    Krishnaswamy, S
    Hao, Q
    von Moltke, LL
    Greenblatt, DJ
    Court, MH
    [J]. DRUG METABOLISM AND DISPOSITION, 2004, 32 (08) : 862 - 869
  • [23] Validation of serotonin (5-hydroxtryptamine) as an in vitro substrate probe for human UDP-glucuronosyltransferase (UGT) 1A6
    Krishnaswamy, S
    Duan, SX
    Von Moltke, LL
    Greenblatt, DJ
    Court, MH
    [J]. DRUG METABOLISM AND DISPOSITION, 2003, 31 (01) : 133 - 139
  • [24] Interactions with other human UDP-glucuronosyltransferases attenuate the consequences of the Y485D mutation on the activity and substrate affinity of UGT1A6
    Kurkela, Mika
    Patana, Anne-Sisko
    Mackenzie, Peter I.
    Court, Michael H.
    Tate, Christopher G.
    Hirvonen, Jouni
    Goldman, Adrian
    Finel, Moshe
    [J]. PHARMACOGENETICS AND GENOMICS, 2007, 17 (02) : 115 - 126
  • [25] Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily
    Mackenzie, PI
    Bock, KW
    Burchell, B
    Guillemette, C
    Ikushiro, S
    Iyanagi, T
    Miners, JO
    Owens, IS
    Nebert, DW
    [J]. PHARMACOGENETICS AND GENOMICS, 2005, 15 (10) : 677 - 685
  • [26] COMPARISON OF SOLUTION CONFORMATIONAL PREFERENCES FOR THE HALLUCINOGENS BUFOTENIN AND PSILOCIN USING 360-MHZ PROTON NMR-SPECTROSCOPY
    MIGLIACCIO, GP
    SHIEH, TLN
    BYRN, SR
    HATHAWAY, BA
    NICHOLS, DE
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1981, 24 (02) : 206 - 209
  • [27] Expression of UGT1A and UGT2B mRNA in human normal tissues and various cell lines
    Nakamura, Akiko
    Nakajima, Miki
    Yamanaka, Hiroyuki
    Fujiwara, Ryoichi
    Yokoi, Tsuyoshi
    [J]. DRUG METABOLISM AND DISPOSITION, 2008, 36 (08) : 1461 - 1464
  • [28] Determination of mRNA Expression of Human UDP-Glucuronosyltransferases and Application for Localization in Various Human Tissues by Real-Time Reverse Transcriptase-Polymerase Chain Reaction
    Ohno, Shuji
    Nakajin, Shizuo
    [J]. DRUG METABOLISM AND DISPOSITION, 2009, 37 (01) : 32 - 40
  • [29] Concise large-scale synthesis of psilocin and psilocybin, principal hallucinogenic constituents of "magic mushroom"
    Shirota, O
    Hakamata, W
    Goda, Y
    [J]. JOURNAL OF NATURAL PRODUCTS, 2003, 66 (06): : 885 - 887
  • [30] Sneitz N., 2009, PHARMACOGENET GENOMI